Pfizer Inc. (PFE) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PFE Revenue Growth
Revenue Breakdown (FY 2025)
PFE's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
PFE Revenue Analysis (2014–2025)
As of May 6, 2026, Pfizer Inc. (PFE) generated trailing twelve-month (TTM) revenue of $63.31 billion, reflecting solid growth of +5.4% year-over-year. The most recent quarter (Q1 2026) recorded $14.45 billion in revenue, down 17.7% sequentially.
Looking at the longer-term picture, PFE's 5-year compound annual growth rate (CAGR) stands at +8.5%, indicating steady revenue expansion. The company achieved its highest annual revenue of $100.33 billion in 2022.
Revenue diversification analysis shows PFE's business is primarily driven by Biopharma Segment (100%). With over half of revenue concentrated in Biopharma Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including JNJ (+3.7% YoY), MRK (+1.2% YoY), and ABBV (+8.6% YoY), PFE has underperformed the peer group in terms of revenue growth. Compare PFE vs JNJ →
PFE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PFECurrent | $63.3B | +5.4% | +8.5% | 24.7% | |
 JNJ | $88.8B | +3.7% | +1.6% | 24.9% | |
 MRK | $64.9B | +1.2% | +9.4% | 36.2% | |
 ABBV | $61.2B | +8.6% | +6.0% | 32.8% | |
 LLY | $65.2B | +47.4% | +21.6% | 45.6% | |
 BMY | $48.2B | +1.8% | +2.5% | 26.3% |
PFE Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $62.58B | -1.6% | $44.01B | 70.3% | $15.44B | 24.7% |
| 2024 | $63.63B | +6.8% | $41.85B | 65.8% | $16.48B | 25.9% |
| 2023 | $59.55B | -40.6% | $30.34B | 50.9% | $5.29B | 8.9% |
| 2022 | $100.33B | +23.4% | $62.09B | 61.9% | $37.55B | 37.4% |
| 2021 | $81.29B | +95.2% | $46.88B | 57.7% | $20.79B | 25.6% |
| 2020 | $41.65B | +1.2% | $29.88B | 71.7% | $9.09B | 21.8% |
| 2019 | $41.17B | -23.3% | $28.55B | 69.3% | $7.51B | 18.2% |
| 2018 | $53.65B | +2.1% | $37.64B | 70.2% | $15.29B | 28.5% |
| 2017 | $52.55B | -0.5% | $36.77B | 70.0% | $14.39B | 27.4% |
| 2016 | $52.82B | +8.1% | $36.87B | 69.8% | $14.27B | 27.0% |
Full PFE Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See PFE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PFE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PFE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPFE — Frequently Asked Questions
Quick answers to the most common questions about buying PFE stock.
Is PFE's revenue growth accelerating or slowing?
PFE maintains +5.4% revenue growth, in line with its 5-year CAGR of +8.5%. TTM revenue stands at $63.3B. Growth rate remains consistent with historical average.
What is PFE's long-term revenue growth rate?
Pfizer Inc.'s 5-year revenue CAGR of +8.5% reflects the sustained expansion pattern. Current YoY growth of +5.4% is near this long-term average.
How is PFE's revenue distributed by segment?
PFE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.